Teva Bows To $1.4bn US Ingrezza IP With Far Future Settlement

Israeli Firm Must Wait To Broaden TD Portfolio With Distant Settlement Deal

Teva has found a settlement deal with Neurocrine over the TD blockbuster Ingrezza.

TEVA
• Source: Shutterstock

More from Legal & IP

More from Generics Bulletin